Novo Nordisk and Novartis will participate in large Danish project on decentralized clinical trials

A consortium of industry players has pooled over DKK 48m (USD 6.2m) to develop a digital platform meant to help recruit patients, collect data, and make it easier to conduct clinical studies – digitally.

A new project with a budget of DKK 48.2m will develop a platform of three apps to collect patient data with severe obesity, diabetic foot ulcers, and urticaria | Photo: Thomas Peter/Reuters/Ritzau Scanpix

Novo Nordisk, Novartis, and Monsenso. The Innovation Fund Denmark and Danish Life science Cluster. Universities, hospitals, and municipalities.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs